Q4 Earnings Estimate for OPCH Issued By Barrington Research

Option Care Health, Inc. (NASDAQ:OPCH) – Equities researchers at Barrington Research lowered their Q4 2024 earnings per share estimates for Option Care Health in a research report issued on Thursday, October 31st. Barrington Research analyst M. Petusky now anticipates that the company will earn $0.32 per share for the quarter, down from their previous forecast of $0.34. Barrington Research has a “Outperform” rating and a $32.00 price objective on the stock. The consensus estimate for Option Care Health’s current full-year earnings is $1.22 per share. Barrington Research also issued estimates for Option Care Health’s Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.28 EPS, Q3 2025 earnings at $0.30 EPS and Q4 2025 earnings at $0.34 EPS.

Option Care Health (NASDAQ:OPCH) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.05. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.22 billion. Option Care Health had a return on equity of 15.30% and a net margin of 4.37%.

OPCH has been the topic of several other research reports. JMP Securities increased their target price on Option Care Health from $36.00 to $37.00 and gave the stock a “market outperform” rating in a report on Monday, September 30th. Truist Financial decreased their target price on Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a report on Friday. Jefferies Financial Group cut Option Care Health from a “buy” rating to a “hold” rating and decreased their price target for the company from $38.00 to $26.00 in a report on Thursday. Finally, Bank of America cut Option Care Health from a “buy” rating to a “neutral” rating and decreased their price target for the company from $43.00 to $29.00 in a report on Wednesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $31.60.

Option Care Health Price Performance

Shares of OPCH stock opened at $24.11 on Friday. The stock’s fifty day moving average is $30.49 and its 200-day moving average is $29.92. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.36 and a current ratio of 1.73. The stock has a market capitalization of $4.12 billion, a PE ratio of 20.26, a PEG ratio of 1.79 and a beta of 1.29. Option Care Health has a 52 week low of $22.84 and a 52 week high of $34.63.

Hedge Funds Weigh In On Option Care Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPCH. Blue Trust Inc. raised its position in shares of Option Care Health by 14.8% during the second quarter. Blue Trust Inc. now owns 2,931 shares of the company’s stock worth $81,000 after purchasing an additional 377 shares during the period. GAMMA Investing LLC raised its position in shares of Option Care Health by 110.6% during the third quarter. GAMMA Investing LLC now owns 897 shares of the company’s stock worth $28,000 after purchasing an additional 471 shares during the period. Trust Point Inc. raised its position in shares of Option Care Health by 2.6% during the third quarter. Trust Point Inc. now owns 24,124 shares of the company’s stock worth $755,000 after purchasing an additional 622 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Option Care Health by 5.4% during the second quarter. Nisa Investment Advisors LLC now owns 13,581 shares of the company’s stock worth $376,000 after purchasing an additional 690 shares during the period. Finally, State of Alaska Department of Revenue raised its position in shares of Option Care Health by 3.8% during the third quarter. State of Alaska Department of Revenue now owns 19,871 shares of the company’s stock worth $621,000 after purchasing an additional 735 shares during the period. Institutional investors own 98.05% of the company’s stock.

Insider Activity at Option Care Health

In other Option Care Health news, CFO Michael H. Shapiro sold 23,217 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.95, for a total transaction of $718,566.15. Following the transaction, the chief financial officer now owns 247,317 shares in the company, valued at approximately $7,654,461.15. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Option Care Health news, CFO Michael H. Shapiro sold 23,217 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.95, for a total transaction of $718,566.15. Following the transaction, the chief financial officer now owns 247,317 shares in the company, valued at approximately $7,654,461.15. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Elizabeth Quadros Betten sold 47,531 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $31.09, for a total value of $1,477,738.79. Following the transaction, the director now owns 21,339 shares in the company, valued at approximately $663,429.51. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.64% of the stock is owned by company insiders.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.